Protecting active pharmaceutical ingredients (APIs), drug products, and biological samples from temperature-induced degradation.
, titled Low Endotoxin Recovery , is a critical guidance document published by the Parenteral Drug Association. It provides a comprehensive framework for understanding, investigating, and mitigating the phenomenon of Low Endotoxin Recovery (LER) in pharmaceutical manufacturing. pda technical report 82
Quantify the severity by determining the speed and extent of endotoxin masking. Quantify the severity by determining the speed and
Introducing specific modulators, bovine serum albumin (BSA), or localized dispersing agents to disrupt surfactant binding. Share public link LER is a condition in
The differences between spikes in validation testing. Share public link
LER is a condition in biological products where endotoxins become "masked" or undetectable by traditional Bacterial Endotoxin Tests (BET), such as the Limulus Amebocyte Lysate (LAL) assay, potentially leading to false-negative results. Key Contents of TR 82
Published in March 2019, PDA Technical Report No. 82 (TR 82) provides a comprehensive, science-based approach to understanding and managing Low Endotoxin Recovery (LER) in biologics. The report offers crucial hold-time study protocols and demasking techniques developed by an industry task force to address how surfactant and chelating agents mask endotoxins from traditional LAL testing. For detailed information on the report, visit PDA . Technical Report No. 82: Low Endotoxin Recovery | PDA
